Update from TD bowieknife 02/06/2014 Update. The

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Understanding ZTO Express's Convertible Note Repurchase Right ZTO Express (Cayman) Inc. (NYSE: ZTO), a key player in the express delivery sector, recently informed its bondholders about their rights regarding the 1.50% Convertible Senior Notes due 2027. The company offers an opportunity for holders to request the repurchase of their notes in cash, giving them a strategic...

A Bold Leap in AI Commercialization Look, fresh off the press, EVERSANA is making some waves. They’ve expanded their AI-powered commercialization platform, aiming to overhaul life sciences operations. Sounds like a mouthful, right? Well, let's break it down. This expansion isn't just a facelift; it's part of a bigger vision to create a nimble, AI-native ecosystem for...

Wabtec Corporation Delivers Strong Third Quarter Results Wabtec Corporation (NYSE: WAB) has announced a solid performance for the third quarter, reporting a notable 4.5% increase in sales, reaching $2.7 billion compared to the same period last year. This growth can be attributed to the robust performance in its freight and transit sectors. The company also shared that the...

Argosy Real Estate Partners and Economic Development Argosy Real Estate Partners, a dedicated private real estate investment manager, has recently shared compelling insights from its Opportunity Zone Economic Impact Analysis. The firm emphasizes its commitment to fostering positive growth in communities by investing in Qualified Opportunity Zones. This analysis showcases...

Vow ASA Invites You to Its Third Quarter 2024 Presentation Vow ASA (OSE: VOW) is gearing up to unveil its much-anticipated report for the third quarter of 2024. Mark your calendars for this significant event on a Tuesday morning, when the company's financial performance and insights will be shared with the world. Presentation Details The results will be available for...